Trending Stock News

ChemoCentryx, Inc. (CCXI) Reaches $10.80 After 9.00% Up Move; Artisan Partners Asset Management Has 1.66 Sentiment

ChemoCentryx, Inc. (NASDAQ:CCXI) Logo

The stock of ChemoCentryx, Inc. (NASDAQ:CCXI) is a huge mover today! The stock increased 1.22% or $0.13 during the last trading session, reaching $10.8. About 90,957 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 81.17% since April 24, 2017 and is uptrending. It has outperformed by 69.62% the S&P500.The move comes after 5 months positive chart setup for the $529.97 million company. It was reported on Apr, 24 by Barchart.com. We have $11.77 PT which if reached, will make NASDAQ:CCXI worth $47.70 million more.

Artisan Partners Asset Management Inc (APAM) investors sentiment increased to 1.66 in 2017 Q4. It’s up 0.65, from 1.01 in 2017Q3. The ratio has increased, as 113 institutional investors increased or opened new equity positions, while 68 trimmed and sold equity positions in Artisan Partners Asset Management Inc. The institutional investors in our database now own: 48.16 million shares, up from 47.38 million shares in 2017Q3. Also, the number of institutional investors holding Artisan Partners Asset Management Inc in top ten equity positions increased from 0 to 1 for an increase of 1. Sold All: 18 Reduced: 50 Increased: 69 New Position: 44.

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company has market cap of $529.97 million. The Company’s lead drug candidate is Avacopan , an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). It has a 30 P/E ratio. The firm also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe CrohnÂ’s diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis.

Among 4 analysts covering ChemoCentryx (NASDAQ:CCXI), 2 have Buy rating, 1 Sell and 1 Hold. Therefore 50% are positive. ChemoCentryx has $16 highest and $1300 lowest target. $14.50’s average target is 34.26% above currents $10.8 stock price. ChemoCentryx had 6 analyst reports since September 3, 2015 according to SRatingsIntel. The firm has “Sell” rating by Zacks given on Thursday, September 3. The firm earned “Overweight” rating on Tuesday, March 13 by JP Morgan. The stock of ChemoCentryx, Inc. (NASDAQ:CCXI) earned “Mkt Outperform” rating by JMP Securities on Tuesday, February 21. The rating was maintained by Cowen & Co with “Hold” on Tuesday, August 8. JMP Securities maintained the shares of CCXI in report on Thursday, August 10 with “Buy” rating. The stock has “Sell” rating by Zacks on Monday, September 21.

Analysts await ChemoCentryx, Inc. (NASDAQ:CCXI) to report earnings on May, 9. They expect $-0.29 EPS, down 141.67% or $0.17 from last year’s $-0.12 per share. After $0.80 actual EPS reported by ChemoCentryx, Inc. for the previous quarter, Wall Street now forecasts -136.25% negative EPS growth.

Investors sentiment increased to 1.3 in Q4 2017. Its up 0.16, from 1.14 in 2017Q3. It improved, as 6 investors sold ChemoCentryx, Inc. shares while 21 reduced holdings. 7 funds opened positions while 28 raised stakes. 23.51 million shares or 1.03% less from 23.75 million shares in 2017Q3 were reported. Wells Fargo Co Mn has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 48,636 shares. Public Employees Retirement Systems Of Ohio owns 69,613 shares. Macquarie Group Inc Ltd invested in 1,500 shares. Panagora Asset Mgmt holds 0.01% or 282,638 shares. Sei Invests owns 2,341 shares. Jpmorgan Chase & stated it has 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). 145,100 are owned by Spark Mgmt Ltd Co. California Public Employees Retirement Sys has 62,800 shares. Royal Savings Bank Of Canada stated it has 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Citadel Advsr Llc owns 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 57,123 shares. Bridgeway Cap Mngmt Incorporated accumulated 52,396 shares. Deutsche Bancorporation Ag invested in 0% or 187,538 shares. 6,107 were reported by Tower Rech Ltd Limited Liability Company (Trc). Piermont Management Inc holds 26,738 shares. Goldman Sachs Gp Inc holds 0% or 267,066 shares.

Bernzott Capital Advisors holds 3.36% of its portfolio in Artisan Partners Asset Management Inc. for 643,111 shares. Channing Capital Management Llc owns 2.03 million shares or 2.71% of their US portfolio. Moreover, Sprott Inc. has 2.15% invested in the company for 186,500 shares. The California-based Kayne Anderson Rudnick Investment Management Llc has invested 1.46% in the stock. Legacy Capital Partners Inc., a Wisconsin-based fund reported 69,840 shares.

Analysts await Artisan Partners Asset Management Inc. (NYSE:APAM) to report earnings on April, 26. They expect $0.72 earnings per share, up 38.46% or $0.20 from last year’s $0.52 per share. APAM’s profit will be $56.11M for 11.25 P/E if the $0.72 EPS becomes a reality. After $0.66 actual earnings per share reported by Artisan Partners Asset Management Inc. for the previous quarter, Wall Street now forecasts 9.09% EPS growth.

The stock decreased 0.77% or $0.25 during the last trading session, reaching $32.4. About 204,263 shares traded. Artisan Partners Asset Management Inc. (APAM) has risen 25.21% since April 24, 2017 and is uptrending. It has outperformed by 13.66% the S&P500.

ChemoCentryx, Inc. (NASDAQ:CCXI) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *